Literature DB >> 33440817

Identification of Risk Factors to Predict the Occurrences of Relapses in Individuals with Schizophrenia Spectrum Disorder in Iran.

Omran Davarinejad1,2, Tahereh Mohammadi Majd2, Farzaneh Golmohammadi2, Payam Mohammadi2, Farnaz Radmehr2, Mostafa Alikhani1,2, Tayebeh Motaei2, Mehdi Moradinazar2, Annette Brühl3, Dena Sadeghi Bahmani3,4,5, Serge Brand1,3,4,6,7.   

Abstract

Schizophrenia Spectrum Disorder (SSD) is a chronic psychiatric disorder with a modest treatment outcome. In addition, relapses are commonplace. Here, we sought to identify factors that predict relapse latency and frequency. To this end, we retrospectively analyzed data for individuals with SSD. Medical records of 401 individuals with SSD were analyzed (mean age: 25.51 years; 63.6% males) covering a five-year period. Univariate and multivariate Penalized Likelihood Models with Shared Log-Normal Frailty were used to determine the correlation between discharge time and relapse and to identify risk factors. A total of 683 relapses were observed in males, and 422 relapses in females. The Relapse Hazard Ratio (RHR) decreased with age (RHR = 0.99, CI: (0.98-0.998)) and with participants' adherence to pharmacological treatment (HR = 0.71, CI: 0.58-0.86). In contrast, RHR increased with a history of suicide attempts (HR = 1.32, CI: 1.09-1.60), and a gradual compared to a sudden onset of disease (HR = 1.45, CI: 1.02-2.05). Gender was not predictive. Data indicate that preventive and therapeutic interventions may be particularly important for individuals who are younger at disease onset, have a history of suicide attempts, have experienced a gradual onset of disease, and have difficulties adhering to medication.

Entities:  

Keywords:  predictions; relapse; schizophrenia spectrum disorder; treatment adherence

Mesh:

Year:  2021        PMID: 33440817      PMCID: PMC7827717          DOI: 10.3390/ijerph18020546

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  52 in total

Review 1.  Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis.

Authors:  Erasmo Saucedo Uribe; Farid Carranza Navarro; Andrea Fernanda Guerrero Medrano; Karen Iscely García Cervantes; Neri Alejandro Álvarez Villalobos; Víctor Daniel Acuña Rocha; Mauricio Méndez Hernández; Juan Manuel Millán Alanís; César Marcelo Hinojosa Cavada; Jorge Alberto Zúñiga Hernández; Stefan Mauricio Fernández Zambrano
Journal:  J Psychiatr Res       Date:  2020-07-30       Impact factor: 4.791

Review 2.  Implementing evidence-based physical activity interventions for people with mental illness: an Australian perspective.

Authors:  Simon Rosenbaum; Anne Tiedemann; Robert Stanton; Alexandra Parker; Anna Waterreus; Jackie Curtis; Philip B Ward
Journal:  Australas Psychiatry       Date:  2015-07-02       Impact factor: 1.369

Review 3.  EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH).

Authors:  Brendon Stubbs; Davy Vancampfort; Mats Hallgren; Joseph Firth; Nicola Veronese; Marco Solmi; Serge Brand; Joachim Cordes; Berend Malchow; Markus Gerber; Andrea Schmitt; Christoph U Correll; Marc De Hert; Fiona Gaughran; Frank Schneider; Florence Kinnafick; Peter Falkai; Hans-Jürgen Möller; Kai G Kahl
Journal:  Eur Psychiatry       Date:  2018-10       Impact factor: 5.361

4.  Serum oxytocin concentrations in current and recent suicide survivors are lower than in healthy controls.

Authors:  Leila Jahangard; Mehran Shayganfard; Farahnaz Ghiasi; Iraj Salehi; Mohammad Haghighi; Mohammad Ahmadpanah; Dena Sadeghi Bahmani; Serge Brand
Journal:  J Psychiatr Res       Date:  2020-05-22       Impact factor: 4.791

5.  Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; Stefan Leucht; Mark Olfson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

6.  The process of responding to stigma in people with schizophrenia spectrum disorders and families: A grounded theory study.

Authors:  Fatemeh Rezayat; Eesa Mohammadi; Masoud Fallahi-Khoshknab
Journal:  Perspect Psychiatr Care       Date:  2019-12-23       Impact factor: 2.186

7.  Experience and the meaning of stigma in patients with schizophrenia spectrum disorders and their families: A qualitative study.

Authors:  Fatemeh Rezayat; Eesa Mohammadi; Masoud Fallahi-Khoshknab; Vandad Sharifi
Journal:  Jpn J Nurs Sci       Date:  2018-05-10       Impact factor: 1.418

8.  A Neural Basis for the Acquired Capability for Suicide.

Authors:  Gopikrishna Deshpande; Madhura Baxi; Tracy Witte; Jennifer L Robinson
Journal:  Front Psychiatry       Date:  2016-08-02       Impact factor: 4.157

Review 9.  Models to predict relapse in psychosis: A systematic review.

Authors:  Sarah Sullivan; Kate Northstone; Caroline Gadd; Julian Walker; Ruta Margelyte; Alison Richards; Penny Whiting
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

View more
  1 in total

1.  Long non-coding RNA-associated competing endogenous RNA axes in the olfactory epithelium in schizophrenia: a bioinformatics analysis.

Authors:  Hani Sabaie; Marziyeh Mazaheri Moghaddam; Madiheh Mazaheri Moghaddam; Nazanin Amirinejad; Mohammad Reza Asadi; Yousef Daneshmandpour; Bashdar Mahmud Hussen; Mohammad Taheri; Maryam Rezazadeh
Journal:  Sci Rep       Date:  2021-12-30       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.